The General Hospital Corporation

Other

The Brigham and Women's Hospital, Inc.

Massachusetts Institute of Technology

Andrew David Luster

David T Scadden

Mark C Poznansky

Philip Leder

Marc Elliot Rothenberg

Jeffrey M Drazen

Eduardo Garcia

Craig M Lilly

Karl Dane Wittrup

Alessandro Angelini

Mindy N Sarafi

Eduardo A Garcia-Zepeda

The present disclosure provides for fusion proteins comprising multipsecific variable regions that bind more than one ELR+ CXC chemokine.

Multiple specificity binders of CXC chemokines

This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. More specifically, specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. Other sites include tumor sites, sites of pathogenic infection, and germ cell bearing sites.

Purposeful movement of human migratory cells away from an agent source

Methods and compositions for diagnosing and treating asthma are provided. The methods involve the discovery of a correlation between an eotaxin gene polymorphism and the ocurrence of asthma.

Methods for diagnosis, prediction and treatment of asthma and other inflammatory conditions based on eotaxin coding sequence polymorphism

Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.

Eotaxin: an eosinophil chemoattractant

Substantially pure nucleic acid molecules encoding the monocyte chemotactic proteins MCP-4 and MCP-5. These molecules and the polypeptides they encode are useful in treating diseases or conditions that: (1) are exacerbated by a local immune response, (2) would benefit from a local immune response, or (3) are caused by infectious agents that gain entry to mammalian cells via the chemokine receptors bound by MCP-4 or MCP-5.

Nucleic acid encoding monocyte chemotactic protein 4

Methods and compositions for diagnosing and treating asthma are provided. The methods involve the discovery of a correlation between an eotaxin gene polymorphism and the occurrence of asthma.

Growing community of inventors

Wellesley, MA, United States of America

Andrew David Luster